Sumitomo Pharma valuation
Valuation
The P/E ratio is 19.2. The average price target of 7 analysts is ¥2,242.86.
Data as of November 15, 2026
Sumitomo Pharma compared with similar companies
Sumitomo Pharma's P/E (trailing 12 months): 19.2, −32% against the median of a group of 11 similar companies (28.4).
| Metric | Sumitomo Pharma | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 19.2 | 28.4 | 17.7 – 50.8 | Middle |
| Forward P/E | 118.4 | 24.0 | 17.8 – 41.4 | High |
| EV/EBITDA | 58.3 | 18.4 | 15.7 – 43.0 | High |
| Price/book | 2.11 | 2.45 | 1.87 – 6.96 | Middle |
| Price/sales | 1.85 | 3.91 | 2.42 – 7.22 | Low |
| Gross margin | 53.3% | 72.2% | 56.8% – 76.3% | Low |
| Operating margin | -0.4% | 18.6% | 12.1% – 23.2% | Low |
| Net margin | 9.4% | 13.8% | 11.3% – 23.3% | Low |
| ROE | 13.3% | 14.7% | 11.4% – 18.5% | Middle |
| Debt/equity | 0.32 | 0.28 | 0.03 – 0.41 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Sumitomo Pharma: valuation over time
On the latest fiscal year's earnings (2026), Sumitomo Pharma's P/E today is 7.50, below the median of its last 8 fiscal years (13.4; between 7.72 and 25.2 from 2017 to 2026). Relative to earnings, the stock costs less than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| Mar 2026 | ¥2,075.50 | ¥268.99 | 7.72 | — | — |
| Mar 2025 | ¥729.00 | ¥59.49 | 12.3 | — | — |
| Mar 2024 | ¥404.00 | -¥792.79 | — | — | — |
| Mar 2023 | ¥810.00 | -¥187.55 | — | ¥21.00 | 2.6% |
| Mar 2022 | ¥1,208.00 | ¥141.99 | 8.51 | ¥28.00 | 2.3% |
| Mar 2021 | ¥1,927.00 | ¥141.50 | 13.6 | ¥28.00 | 1.5% |
| Mar 2020 | ¥1,403.00 | ¥102.58 | 13.7 | ¥28.00 | 2.0% |
| Mar 2019 | ¥2,737.00 | ¥122.39 | 22.4 | ¥26.00 | 0.9% |
| Mar 2018 | ¥1,786.00 | ¥134.53 | 13.3 | ¥18.00 | 1.0% |
| Mar 2017 | ¥1,838.00 | ¥72.97 | 25.2 | ¥18.00 | 1.0% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- ¥909.75B
- Enterprise value
- ¥971.68B
- PEG
- 1.93
- EV/revenue
- 1.97
Profitability and growth
- ROA
- -0.1%
- ROIC
- -0.2%
- Revenue growth (year over year)
- 15.0%
- Earnings growth (year over year)
- -78.5%
Financial health
- Total cash
- ¥77.76B
- Total debt
- ¥139.69B
- Current ratio
- 1.36
- Quick ratio
- 0.93
- Altman Z-Score
- 2.15
- Piotroski F-Score
- 5.00
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- ¥2,242.86
- Median price target
- ¥2,500.00
- High price target
- ¥2,800.00
- Low price target
- ¥1,500.00
- Analysts with a price target
- 7
- Consensus
- Buy
- Forward EPS
- ¥17.13
- EPS estimate, current year
- ¥191.95
Shares and trading
- Beta
- 0.48
- Average volume
- 4M
- Shares outstanding
- 448.59M
- Float
- 238.43M
- Institutional ownership
- 23.2%
- Insider ownership
- 48.6%
